Daxor Corporation, (NYSE MKT:
DXR) an investment company with medical instrumentation
and biotechnology operations, today announced the
presentation of a study on Radioisotope Blood Volume
Measurement in Hemodialysis Patients. A study headed by Dr.
David Goldfarb was presented at the recent American Society
of Nephrology (ASN) annual meeting held in San Diego. Dr.
Goldfarb performed this work with Drs. Sonika Puri, Jun-Ki
Park, Aditya Matoo and Frank Modersitzki
The study performed at the New York Harbor VA Healthcare
Center was the first study ever performed where complete
blood volume measurements were performed on renal dialysis
patients before they underwent renal dialysis and shortly
after dialysis was completed. Renal dialysis is usually
performed three times a week on patients who have kidney
failure. The renal dialysis process involves filtering a
patient's blood obtained from a large vein, and returning the
blood to another vein over a period of two to four hours.
Without dialysis such patients would soon die from an
accumulation of toxic waste products. Renal dialysis patients
are sometimes able to obtain a donated kidney which enables
them to live without dialysis. Only a small percentage of
kidney failure patients, however, are able to obtain a
A dialysis procedure removes toxic waste products as well as
excess fluid from the body of these patients who produce no
urine because they have total kidney failure. 65% of renal
dialysis patients die within 5 years of beginning dialysis.
25% of patients have a so-called crash episode at least once
a year in which blood pressure drops to extremely low levels.
This study by Dr. Goldfarb demonstrated that patients have
significant variability in response to dialysis treatment as
to whether the fluid removed comes from their blood volume or
from their extra cellular water.
At the present time physicians administering dialysis
treatment do not have an accurate way of evaluating the
source of the fluid being removed from the patient. The use
of a blood volume measurement in conjunction with a simple
crit-line, which measures hematocrit concentration, can
enable a physician to determine, during dialysis, the source
of the fluid being removed from the patient and potentially
avoid a severe drop in blood pressure.
Dr. Goldfarb is the medical director of hemodialysis at the
New York Harbor VA Healthcare Center, and Professor of
Medicine and Physiology at NYU School of Medicine. Dr.
Goldfarb is willing to discuss his findings with medical
personnel. He can be reached at the New York Harbor VA. He
prefers to be initially contacted via e-mail at email@example.com. The
study can be found on Daxor's website at www.Daxor.com. The link to this
study is http://www.daxor.com/pdfs/ASN2012_Park_Radioisotope.pdf.
Daxor Corporation manufactures and markets the BVA-100, which
is used in conjunction with Volumex, Daxor's single use
diagnostic kit. For more information regarding Daxor
Corporation's Blood Volume Analyzer BVA-100, visit Daxor's
website at www.Daxor.com.